Access cutting-edge pancreatic cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access pancreatic cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pancreatic cancer treatment provided free
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Sponsor: Genentech, Inc.
Check if you qualify for this pancreatic cancer clinical trial in New Haven, CT
If you're searching for pancreatic cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.